Identification of genes related to macrophage polarization and mitochondrial dysfunction in hepatocellular carcinoma and prognostic modeling via LASSO-Cox regression.
This study screened candidate prognostic genes associated with macrophage polarization and mitochondrial dysfunction based on bioinformatics analysis and established a prognostic model related to macrophage polarization and mitochondrial dysfunction associated with HCC.
Abstract
Aim
Hepatocellular carcinoma (HCC) is the most common primary liver cancer in adults, with increasing incidence. It is helpful to establish a prognostic risk prediction model related to macrophage polarization and mitochondrial dysfunction associated with HCC.
Methods
Cox and Least Absolute Shrinkage and Selection Operator (LASSO) regression, Gene Set Variation Analysis (GSVA) and Gene Set Enrichment Analysis (GSEA), protein-protein interaction (PPI) network.
Results
A total of 7 model genes (EZH2, G6PD, HMGA2, MAGEB2, PYCR1, SLC7A11, and SPP1) were identified. And the LASSO-Cox model showed preliminary prognostic predictive performance in the TCGA-LIHC cohort (0.9 > AUC > 0.7), with decision curve analysis (DCA) showing clinical potential, particularly in the third year. GSEA revealed that genes associated with Liver hepatocellular carcinoma (LIHC) exhibited enrichment in functions and pathways, notably including FCGR3A Mediated IL10 Synthesis, etc. GSVA indicated multiple pathways were significant in both Low-Risk and High-Risk groups, such as the biocatamcm pathway (p < 0.05). The PPI Network shows connections among G6PD, SLC7A11, HMGA2, and EZH2, with GeneMANIA predicting their interactions with similar function genes.
Conclusion
Our study screened candidate prognostic genes associated with macrophage polarization and mitochondrial dysfunction based on bioinformatics analysis and established a prognostic model.
This KIF20A/NDC80-based model is a reliable prognostic tool for HCC; its immunotherapeutic utility remains exploratory and requires prospective validation.
Yu Yan, Zhen-Guo Liu, Dawei Zhou et al.· Cancer Biomarkers· 0 citations
Background Hepatocellular carcinoma (HCC) demonstrates significant prognostic variability that is not entirely accounted for by traditional staging systems. Necrosis by sodium overload (NECSO) is an emerging programmed cell death pathway, but its clinical relevance in HCC remains undefined. Therefore, this study aimed...
Jun-Ze Chen, Jia-Mei Li, Zhi-Yong Lin et al.· Journal of Gastrointestinal...· 0 citations
A robust 4‐MQRG signature comprising ANXA10, BAMBI, AKR1B15, and SPINK1 was established, which revealed that patients classified as high risk had significantly shorter overall survival compared to their low‐risk counterparts, thus offering valuable biomarker support for personalized therapeutic approaches in HCC.
Bin-Bin Li, Li-Jun Zeng, Zhi-Long He et al.· Drug development research (P...· 0 citations
Hepatocellular carcinoma (HCC) is one of the malignant tumors with high incidence and mortality rates worldwide. Given the poor prognosis of patients with HCC, it is crucial to explore the molecular mechanisms underlying HCC development and to evaluate prognostic markers. Differential expression analysis followed by un...
Yu-Xian Liu, Xing-Jie Chen, Jun-Yuan Zhang et al.· International Journal of Mol...· 0 citations
Background and Aims Dysregulated lipid metabolism contributes to hepatocellular carcinoma (HCC) progression, but the prognostic value and mechanistic roles of lipid metabolism-related long noncoding RNAs (LRLs) remain insufficiently characterized. This study aimed to construct and validate an LRL-based prognostic model...
Li-Xin Liu, Yu-Hao Fan, Hao Zou et al.· Journal of Clinical and Tran...· 0 citations
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality worldwide and exhibits substantial molecular heterogeneity, highlighting the need for reliable prognostic biomarkers and therapeutic targets. Increasing evidence suggests that autophagy plays a critical role in HCC progre...
Melika Amelimojarad, Mandana Amelimojarad, S. M. Ayyoubzadeh· Discover Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.